GSM Foils Ltd

GSM Foils Limited reported robust financial results for Q4 FY26, with revenue reaching ₹81.69 crores, a significant 79.1% year-on-year increase. PAT for the quarter grew by 83.6% YoY to ₹6.28 crores, with PAT margin improving by 20 basis points to 7.7%. For the full fiscal year FY26, the company achieved a revenue of ₹258.15 crores, marking a strong 92.9% YoY growth, and EBITDA stood at ₹29.78 crores, up 95.9% YoY. The FY26 PAT margin expanded by 50 basis points to 7.7%, underscoring sustained operational efficiency and scale benefits.

The Ahmedabad manufacturing facility is ramping up well, currently operating at 25-30% utilization. Management aims to achieve optimal utilization by the end of FY27. At optimal capacity, this plant is expected to generate ₹30-35 crores in revenue per month. Combined with the Vasai plant, which currently generates ₹25-28 crores per month and has potential for an additional ₹6-7 crores, the company targets a total monthly run rate of ₹60 crores by March 2027. This expansion is crucial for supporting growth and catering to an expanding customer base in western and northern regions.

Global conflicts, particularly involving Iran, Israel, and the US, have significantly impacted the global supply chain, leading to a tremendous increase in prices for metals like aluminium and petrochemical derivatives used in pharmaceutical packaging. While GSM Foils faced some pressure in March due to these rising costs, they were eventually passed on to customers. Management noted that the situation's normalization timeline remains uncertain, but the company's ability to pass on costs helps sustain margins, with a target to maintain current EBITDA levels around 11.5% for FY27.

The company experienced high receivables in March 2026, primarily due to funds being stuck with pharma companies facing issues with LCs and export payments. However, a significant portion (₹30-40 crores) was recovered in early April. Management emphasized that efficient working capital management, including maintaining a 60-70 day receivables cycle in the pharma sector, is a key competitive advantage. The recent ₹15 crore debt facility from ICICI Bank also helped manage cash flow and maintain good inventory levels during this period.

GSM Foils' growth strategy continues to focus on diversification and strong operational execution. While the immediate focus is on ramping up the Ahmedabad plant and serving existing clients, the company is planning for future capex towards forward integration. This will involve setting up specialized printing or conversion units for pharmaceutical packaging, which could potentially double current margins. An announcement regarding these capex plans is expected within a quarter or two, with implementation possibly by the end of FY27.

Management highlighted that their competitive edge lies in their volume, which makes them more cost-effective, and their strong working capital management capabilities. By leveraging funds from rights issues and bank ODs, they can offer necessary credit to clients, a critical factor in the pharma industry where payments can be delayed up to 120-150 days. The primary risk identified is the inability to manage working capital effectively, as money doesn't sink but can come late. The company maintains conservative credit checks, especially for new clients in Ahmedabad, to mitigate this risk.